Abstract
This novel fibroblast-based myeloid-stromal pathotype could predict radiographic progression at 1 year in active RA patients which may contribute to the shift of therapeutic decision in RA.
Introduction
Rheumatoid Arthritis (RA) is a highly heterogeneous autoimmune disease. While clinical scores like the Disease Activity Score 28 (DAS28) are used to guide "treat-to-target" strategies, they often fail to capture the full biological picture. Approximately 20% of patients who achieve clinical remission still experience progressive joint destruction visible on X-rays.
Traditional synovial classification systems have focused primarily on infiltrating immune cells—the "seeds" of inflammation. However, the synovial "soil"—comprising stromal elements like fibroblasts and blood vessels—plays a critical role in disease persistence and structural damage. This study introduces a new classification system that incorporates these stromal markers to better predict long-term radiographic outcomes.
Methods
The researchers conducted a prospective cohort study involving 150 RA patients at Sun Yat-Sen Memorial Hospital. Synovial tissue was obtained via needle biopsy of the knee at baseline.
Immunohistochemistry and Classification
Tissue samples were stained for six markers: CD20 (B cells), CD38 (plasma cells), CD3 (T cells), CD68 (macrophages), CD31 (endothelial cells), and CD90 (sublining fibroblasts). Using Principal Component Analysis (PCA), the team developed a three-tier pathotype system:
- Myeloid-stromal: Characterized by high scores for macrophages (SL-CD68), blood vessels (CD31), or fibroblasts (CD90).
- Lymphoid: Defined by high B cell (CD20) scores with lower stromal involvement.
- Paucicellular: Low density of all measured markers.
The primary endpoint was radiographic progression at one year, defined as an increase of $\ge$ 0.5 units in the modified total Sharp score (mTSS).
Results
The myeloid-stromal pathotype emerged as a significant predictor of joint damage. At the one-year mark, 43.7% of patients in the myeloid-stromal group showed radiographic progression, compared to 23.1% in the lymphoid group and only 7.7% in the paucicellular group ($p = 0.011$).
Predictive Power and Clinical Correlation
After adjusting for confounding factors such as age, sex, and disease duration, the myeloid-stromal pathotype maintained an Adjusted Odds Ratio (AOR) of 3.199 for predicting 1-year progression. Furthermore, patients with this signature had the lowest rates of Boolean remission at 3, 6, and 12 months.
Correlation analysis revealed that specific cell-type scores, particularly SL-CD68 and CD90, correlated more strongly with structural damage (mTSS) than traditional histological measures like the Krenn synovitis score. This underscores that the specific cellular composition of the synovium is more informative than general inflammation levels.
Discussion
These findings highlight the active role of stromal cells, particularly CD90+ sublining fibroblasts, in driving bone erosion and therapeutic resistance. By integrating myeloid and stromal markers, clinicians can identify high-risk patients who may require more aggressive or targeted therapeutic interventions from the outset.
While this study provides a robust framework using accessible immunohistochemistry, future research should aim to validate these findings in larger, multi-center cohorts. Additionally, advanced techniques like single-cell RNA sequencing could further refine the identification of specific fibroblast subsets that contribute most to joint destruction.
Conclusion
The inclusion of fibroblast and stromal markers into synovial pathotyping significantly improves the prediction of radiographic progression in RA. This "myeloid-stromal" signature represents a high-risk biological profile that could fundamentally shift therapeutic decision-making toward more personalized medicine in Rheumatoid Arthritis.
Summary updated